SunTrust Robinson Humphrey Terminates Medivation Inc(NASDAQ:MDVN)

Brokerage firm SunTrust Robinson Humphrey Terminates its rating on Medivation Inc(NASDAQ:MDVN). Previously, the analysts had a Neutral rating on the shares. The rating by SunTrust Robinson Humphrey was issued on Sep 30, 2016.

In a different note, On Aug 23, 2016, Citigroup said it Downgrades its rating on Medivation Inc. In the research note, the firm Raises the price-target to $73.00 per share. The shares have been rated ‘Hold’ by the firm. On Aug 23, 2016, BMO Capital said it Maintains its rating on Medivation Inc. In the research note, the firm Raises the price-target to $67.16 per share. The shares have been rated ‘Market Perform’ by the firm. On Aug 22, 2016, Barclays said it Downgrades its rating on Medivation Inc. In the research note, the firm Raises the price-target to $70.00 per share. The shares have been rated ‘Equal-weight’ by the firm. On Aug 22, 2016, Brean Capital said it Downgrades its rating on Medivation Inc. The shares have been rated ‘Hold’ by the firm. On Aug 22, 2016, Wedbush said it Downgrades its rating on Medivation Inc. The shares have been rated ‘Neutral’ by the firm. On Aug 22, 2016, Wedbush said it Downgrades its rating on Medivation Inc. The shares have been rated ‘Neutral’ by the firm.

Medivation Inc(MDVN) last announced its earnings results on Aug 9, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $206.16M. Analysts had an estimated revenue of $212.74M. Earnings per share were $0.29. Analysts had estimated an EPS of $0.27.

Several Insider Transactions has been reported to the SEC. On Jun 6, 2016, Andrew Kenneth William Powell (SVP, General Counsel & Crp Sec) sold 2,578 shares at $60.42 per share price.Also, On May 9, 2016, Rick Bierly (CFO (former) sold 10,340 shares at $59.98 per share price.On Mar 16, 2016, Dawn Svoronos (director) sold 6,000 shares at $38.90 per share price, according to the Form-4 filing with the securities and exchange commission.

Medivation Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma Inc. has one commercial product XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States Europe and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab an immune modulatory anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech Ltd.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Medivation Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Medivation Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.